Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2020 Expert Video Report on 1st line ICI for gastro oesophageal cancer

Reporting from the ESMO Virtual Congress 2020, Yelena Janjigian comments on practice changing results with first-line immune checkpoint inhibitor plus chemotherapy in advanced gastric, gastro-oesophageal junction or oesophageal cancers. She details results that are both, clinically meaningful and statistically significant in terms of progression-free and overall survival, while there were no new signals regarding tolerance.


  • LBA6_PR - Nivolumab (NIVO) Plus Chemotherapy (CT) Versus CT in First-Line (1L) Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC)/Esophageal Adenocarcinoma (EAC): First Results of the CheckMate 649 Study
  • LBA7_PR - Nivolumab with chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric or gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
  • LBA8_PR - Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study

This video was supported with grants from Daiichi Sankyo and Roche

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.